US database study: Burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis

Anna Forsythe; Gareth Lewis; Robyn Jordan; George R. Thompson

doi:10.2217/cer-2020-0019

US database study: Burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis

Anna Forsythe, Gareth Lewis, Robyn Jordan, George R. Thompson

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations.

Original language	English (US)
Pages (from-to)	573-584
Number of pages	12
Journal	Journal of Comparative Effectiveness Research
Volume	9
Issue number	8
DOIs	https://doi.org/10.2217/cer-2020-0019
State	Published - Jun 2020
Externally published	Yes

Keywords

burden
fungal
immunocompromised
infection
systemic mycoses

ASJC Scopus subject areas

Health Policy

Access to Document

10.2217/cer-2020-0019

Cite this

@article{71e4efd2fbe54711839d2c4c5bb28629,

title = "US database study: Burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis",

abstract = "Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations. ",

keywords = "burden, fungal, immunocompromised, infection, systemic mycoses",

author = "Anna Forsythe and Gareth Lewis and Robyn Jordan and Thompson, {George R.}",

note = "Funding Information: G Lewis and R Jordan are employees of Mayne Pharma, which sponsored the research. A Forsythe is an employee of Purple Squirrel Economics, which acted as a consultant to Mayne Pharma. GR Thompson III acted as a consultant to Mayne Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. K Sandman of Purple Squirrel Economics provided editorial support. This work was sponsored by Mayne Pharma. Publisher Copyright: {\textcopyright} 2020 ",

year = "2020",

month = jun,

doi = "10.2217/cer-2020-0019",

language = "English (US)",

volume = "9",

pages = "573--584",

journal = "Journal of Comparative Effectiveness Research",

issn = "2042-6305",

publisher = "Future Medicine Ltd.",

number = "8",

}

TY - JOUR

T1 - US database study

T2 - Burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis

AU - Forsythe, Anna

AU - Lewis, Gareth

AU - Jordan, Robyn

AU - Thompson, George R.

N1 - Funding Information: G Lewis and R Jordan are employees of Mayne Pharma, which sponsored the research. A Forsythe is an employee of Purple Squirrel Economics, which acted as a consultant to Mayne Pharma. GR Thompson III acted as a consultant to Mayne Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. K Sandman of Purple Squirrel Economics provided editorial support. This work was sponsored by Mayne Pharma. Publisher Copyright: © 2020

PY - 2020/6

Y1 - 2020/6

N2 - Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations.

AB - Aim: This study evaluated burden of illness in immunocompromised patients with systemic mycoses (SM) eligible for itraconazole treatment, specifically, histoplasmosis, blastomycosis and aspergillosis. Methods: A cross-sectional study used an electronic medical record network integrating information from 30 US hospitals, including >34 million patients, to evaluate burden and healthcare resource utilization over 6 months following initiation of antifungal therapy. Results: Symptomatic burden experienced by each of the otherwise healthy or age >65 or immunosuppressed cohorts receiving antifungal therapy for SM was comparable but significantly greater in cancer or HIV patients and transplant recipients. Across groups, there was substantially higher healthcare resource utilization in patients with SM versus matched controls without SM. Conclusion: The total impact of SM is particularly severe in high-risk or vulnerable populations.

KW - burden

KW - fungal

KW - immunocompromised

KW - infection

KW - systemic mycoses

UR - http://www.scopus.com/inward/record.url?scp=85087466732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087466732&partnerID=8YFLogxK

U2 - 10.2217/cer-2020-0019

DO - 10.2217/cer-2020-0019

M3 - Article

C2 - 32316748

AN - SCOPUS:85087466732

VL - 9

SP - 573

EP - 584

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 8

ER -

US database study: Burden and healthcare resource utilization in adults with systemic endemic mycoses and aspergillosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this